T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results
Received record quarterly sepsis test panel orders and strengthened balance sheetLEXINGTON, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems,...
Antimicrobial
Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation
QIDP designation for Biologics provides FDA Priority Review statusLOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc....
Recce Pharmaceuticals Announces First Cohort Dosed in RECCE® 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial
Highlights: First cohort in Phase I/II urinary tract infection (UTI) rapid infusion intravenous (IV) study successfully dosed 2,500mg of RECCE®...
Oxford University scientists’ AI diagnostic test accurately identifies known respiratory viruses in minutes
Breakthrough in diagnostics testing enables ‘facial recognition for germs’ Collaboration with John Radcliffe Hospital used AI to identify respiratory viruses...
Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax
-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones-- Next procurement...
T2 Biosystems Announces Conversion of Approximately Twenty Percent of CRG Term Loan into Equity
LEXINGTON, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens...
CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants
BERKELEY HEIGHTS, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification and use of genomic variants...
OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments
Following final assembly and successful testing, a batch of ten Unyvero A30 instrument systems has been receivedLatest C-Series Unyvero A30...
CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath
BERKELEY HEIGHTS, N.J., June 21, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases
WAKEFIELD, MA, June 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical...
ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens
YONKERS, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...
Aridis Pharmaceuticals’ AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)
LPAD may provide alternative pathways for streamlined product approvalLOS GATOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc....
Breakthrough Solution for Fragile Skin: Covalon’s IV Clear® Dressing Recommended by Physicians at a Top 10 U.S. Children’s Hospital and Epidermolysis Bullosa Center of Excellence
Anesthesiologists recommend Covalon’s gentle and effective silicone solution over acrylic dressings for securing vascular insertion sites in Epidermolysis Bullosa patients...
Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") today announces it has been awarded...
Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform
Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism.Strong investigator enthusiasm and continued robust...
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida PanelLEXINGTON, Mass., June 05, 2023 (GLOBE NEWSWIRE) --...
T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History
LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens...
Cormedix Inc. To Present At The Jefferies Healthcare Conference
BERKELEY HEIGHTS, N.J., May 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
T2 Biosystems Announces First Quarter 2023 Financial Results
Filed FDA submission for T2Biothreat Panel, implemented a restructuring program and announced exploration of strategic alternativesLEXINGTON, Mass., May 23, 2023...